Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for GRFS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for GRFS and 80,000+ other tickers.
See exactly how GRFS's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GRFS and 80,000+ other tickers.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides…
Grifols, S.A. (NASDAQ: GRFS - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 7,001,241 shares, a growth of 105.0% from the September 15th total of 3,414,455 shares. Based on an average daily volume of 808,104 shares, the days-to-cover ratio is
Grifols (NASDAQ: GRFS - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Earnings and Valuation This table compares Grifols and
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?
Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on operations.
Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.